Scientists developed sulthiame, an oral drug reducing breathing pauses in sleep apnea patients The phase 2 trial showed 47% apnea reduction and improved oxygenation with sulthiame doses Sulthiame stabilises respiratory brain signals and increases airway muscle activity during sleep
